EGFR and non-small cell lung carcinoma: Erlotinib is an orally administered, reversible TKI indicated as first-line treatment for advanced NSCLC in patients with activating EGFR mutations and as second- and third-line treatment in patients with EGFR wild-type NSCLC (Timmers et al., 2015).